all news

Our partners are building great companies. We love to share their stories.

Wed, 22 Mar 2023 BioPharma Dive

At EpiBiologics, a pair of Genentech alumni wants to make next-gen protein degraders

Wed, 22 Mar 2023 FierceBiotech

Novo Nordisk pens $745M biobucks pact with Dewpoint to tackle insulin resistance, diabetes complications

Thu, 9 Mar 2023 QurAlis

QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases

Wed, 8 Mar 2023 Tessa Therapeutics – Cancer Immunotherapy Treatments

Tessa Therapeutics Enters into Cooperative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute

Tue, 7 Mar 2023

Noema Pharma raises crucial financing for treatments

Mon, 6 Mar 2023 FierceBiotech

Armed with $60M series A and Lilly's backing, Volastra enters clinic via Amgen cancer med

Thu, 2 Mar 2023

Folx Health Named one of Fast Company's 50 Most Innovative Companies 2023

Mon, 27 Feb 2023 FierceBiotech

What can bats, naked mole rats and Jaws tell us about human biology? Paratus is on a $100M mission to find out

Wed, 8 Feb 2023 HIT Consultant

Faro Health Secures $20M to Streamline Smart Clinical Trials

Tue, 7 Feb 2023

Ankyra Therapeutics Announces Collaboration to Evaluate ANK-101 in Early Clinical Trials Focused on Lung Cancer

Wed, 25 Jan 2023 Business Wire

KSQ Therapeutics Announces Ono Pharmaceutical Co., Ltd. is Acquiring Multiple Research-Stage Oncology Programs Identified with KSQ’s CRISPRo

Tue, 24 Jan 2023 BioSpace

Polaris Portfolio Companies Named Among Top Life Sciences Startups to Watch in 2023 | BioSpace

Thu, 12 Jan 2023 Ellensburg Daily Record

LCvista to Merge with Prolaera, Creating Market Leader in Accounting Learning and Compliance Management Solutions

Wed, 11 Jan 2023

AgBiome Signs a Commercial Distribution and Supply Agreement With Summit Agro Mexico (SAM) for Howler Fungicide

Mon, 9 Jan 2023 Business Wire

TRexBio Announces Collaboration and License Agreement with Lilly to Develop and Commercialize Novel Therapies for Immune-Mediated Diseases

Mon, 9 Jan 2023 GlobeNewswire News Room

Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology

Fri, 6 Jan 2023 India - PRNewswire

Jnana Therapeutics Announces FDA Clearance of IND Application for JNT-517 for the Treatment of Phenylketonuria

Thu, 5 Jan 2023 citybiz

ByHeart to Acquire Cascadia Nutrition

Wed, 4 Jan 2023 FierceBiotech

Hummingbird Bio buzzes Synaffix for $150M ADC licensing deal

Mon, 12 Dec 2022 Tessa Therapeutics – Cancer Immunotherapy Treatments

Tessa Therapeutics Announces Updated Safety, Efficacy and Biomarker Data from Phase 2 Trial of Autologous CD30.CAR-T Therapy (TT11) in Relap

Thu, 8 Dec 2022 PR Newswire

QurAlis Receives Health Canada Clinical Trial Application Authorization for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS

Thu, 1 Dec 2022

August Bioservices Closes $65M Series B

Tue, 29 Nov 2022 Medical Marketing & Media

AstraZeneca expands oncology portfolio with $320M deal for Neogene Therapeutics

Tue, 15 Nov 2022 BioSpace

Roche Doubles Down on Jnana's RAPID Platform in $2B Deal

Thu, 10 Nov 2022

Ankyra Therapeutics Presents Positive Preclinical Data Supporting Advancement of ANK-101 into Clinical Studies for Treatment of Solid Tumors

Mon, 7 Nov 2022

Tessa Therapeutics, Baylor College of Medicine Execute Agreement For Global Commercial Rights to 'Off-the-Shelf' CAR-T Platform

Fri, 4 Nov 2022 Drug Discovery and Development

PathAI presents data on using AI to aid liver research and NASH drug development

Mon, 24 Oct 2022 PR Newswire

Cohere Health and Humana Expand Partnership to Further Improve Physician and Member Experiences

Thu, 20 Oct 2022

AgBiome receives EPA approval for new Esendo™ fungicide

Tue, 18 Oct 2022 GlobeNewswire

Noema Pharma Receives FDA Fast Track Designation for basimglurant (NOE-101) in Trigeminal Neuralgia

This website is not an advertisement. This website is intended solely to provide general business information on Polaris Partners and any affiliates thereof (collectively, “Polaris”). Nothing on this website should be construed as an offer of investment advisory services by Polaris or a solicitation or an offer of interests in any Polaris fund. Visitors to this website are not to construe the contents of this website or any prior or subsequent communication from Polaris or any of its representatives, as legal, tax or investment advice. References to specific companies are for illustrative purposes only and do not represent all of the companies recommended for advisory clients. Such references are not intended to be, and should not be interpreted as, recommendations or investment advice. All information has been obtained from sources believed to be reliable, but its accuracy is not guaranteed, and Polaris disclaims any duty to update any of the information and data contained herein. Certain statements may be deemed forward-looking, but any such statements are not guarantees of any future performance and actual results or developments may differ materially from those discussed. There is no guarantee that investment objectives will be achieved or that any particular investment will be profitable. Past performance does not guarantee future results. Where applicable, figures include investments made directly and indirectly by the Polaris Main Funds and may include co-investments with the Polaris Growth Funds and the Polaris Innovation Funds. Please see the complete list of investments here, as well as the Terms of Use for additional information and disclosures.


The endorsements of current or past portfolio company executives are provided as illustrative examples and designed to demonstrate the benefits to portfolio companies of partnering with us. These statements are primarily aimed at prospective portfolio companies and not intended to solicit investors. The portfolio companies covered in these endorsements do not represent all portfolio company investments we have made. The experiences highlighted in these testimonials are solely those of the executives profiled and may not necessarily represent or be indicative of the current, past, or future experiences of other portfolio companies. Past results and experiences discussed are not indicative, or a guarantee of future results and experiences. We have not provided cash or other type of compensation in exchange for receiving these endorsements. We do not believe there are typically any material conflicts associated with providing these endorsements. The compensation of our portfolio company executives is primarily driven by the performance of their respective portfolio companies and any discretion we exercise in such compensation determinations is not influenced by whether an executive has provided a favorable statement. Additionally, the economic interests of our portfolio companies’ executives are generally well-aligned with ours and those of our investors. Nevertheless, the fact that these endorsements have been provided by individuals whose compensation we exercise a certain level of control over may incentivize them to provide favorable evaluations of their experiences working with us.